display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced mGC or mGEJC
mGC or mGEJC - L2 - all populationmGC or mGEJC - L2 - PDL1 positive
pembrolizumab alone KEYNOTE-061 ... KEYNOTE-061 ...

Study type: